<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
image©peshkova-stock.adobe.com1.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Life science insights: Looking back at 2018

As we come to the end of 2018, we look back at some of the interviews, case studies, and insights shared by senior executives in the life sciences and investment community. 

Case studies: From fundraising and deal making to product development

Life sciences CEOs talk through the scientific, business, and financial developments achieved by their companies. This includes significant finance rounds such as NMD Pharma’s €38 million Series A, CMR Surgical’s $100 million Series B, and Galecto Biotech’s €79 million Series C; partnering activity such as PharmaKrysto’s licensing deal with Rutgers University and Zilico’s strategic deal with MaxHealth Medicine Group; and a spotlight on digital health start-ups such as Aparito, Grace Cooling, and Cognetivity Neurosciences. Take a look at case studies from Evox Therapeutics, Dyadic International, Novoheart, Endomag, STORM Therapeutics, and more… 

Investorviews: An inside look at some of Europe’s leading VCs

Venture capital firms from the Nordics, UK, and Switzerland discuss their investment criteria and how they work with portfolio companies, and give their take on investment trends and the latest developments in biotech, medtech, medical devices, and digital health. Read interviews with Novo Seeds, Industrifonden, HealthCap, Hadean Ventures, NCL Technology Ventures, and MTIP. 

Expert insights: Industry partners share their know-how across key strategic issues

Discover how biotech and medtech IP strategies diverge with Gill Jennings & Every, how AI and data can add value in healthcare with CMS, what life sciences companies need to know about pre-approval access with Inceptua, how to access US government funds for R&D with Covington, how much experimental data is enough in a European patent application with Appleyard Lees, how to address the challenges of ownership structures with Xplico, why a surge in UK pharma and biotech patents demonstrates investor confidence with Marks & Clerk, the evolving risks facing life sciences companies and the specialist insurance policies available to the sector with Gallagher, and key IPO considerations with Allen & Overy. 

Reports: Tracking sentiment among the life sciences investment and C-suite community

In September, LSX published the inaugural C-Suite Challenges in Life Sciences Survey to examine the obstacles facing companies. Download the full report for the survey findings, and read expert report contributions from Covance, CMS, Marks & Clerk, Epidarex Capital, Executive Women in Bio, and more. Better understand investors’ views on the market via the key findings from the 2nd Investor Perception Survey or register to receive the 2019 edition, which will be released in February 2019. 

Videos and webinars: From award winners to an advanced therapies deep dive

Last month the life sciences community celebrated the Lifestars Awards 2018 at a gala dinner in London. Artios Pharma, Eli Lilly, LSP, F-Star, Allogene and Hookipa Pharma were among the companies who took home trophies. Watch the winners’ videos here. You can also listen to on-demand webinars covering funding, commercialisation and market access for advanced therapies, as well as whistleblowing in life sciences. 

View all content here.

 

Feature image © peshkova  – stock.adobe.com

LSX
Written By

Add Your Response